PDX Model Cohort
Glioblastoma Xenograft Models
A robust cohort of rare and meticulously curated Glioblastoma Patient-derived xenograft models directly established from primary, late-stage, and pre-treated patient tumors to support your glioblastoma cancer drug development research.
Summary
Champions Oncology has established an advanced cohort of Glioblastoma xenograft models, providing a comprehensive platform for glioblastoma research. Our glioblastoma malignancy bank includes 30* PDX models derived from patient samples, preserving their original molecular and clinical characteristics while minimizing genetic drift commonly seen in passaged models. Additional details on these models are available through Champions’ Model Select®.
(*Model numbers fluctuate as our dataset continuously evolves.)
Champions' leading Glioblastoma xenograft models cohort showcases low-passage models, each reflecting key clinical characteristics, mutations, and pretreatment history.
Access to one of the largest bank of glioblastoma xenograft models with clinically relevant molecularand pathological characteristics on the market.
Access to highly characterized PDX models with High Complexity Flow Cytometry, WES, RNAseq, Proteomics and Phosphoproteomics.
Includes models pretreated with advanced therapies like EGFR antibody-drug conjugate, BTK inhibitors, Temozolomide, Bevacizumab, and more.